399 related articles for article (PubMed ID: 19456274)
21. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
23. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
24. 17Beta-estradiol inhibits 11beta-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes.
Tagawa N; Yuda R; Kubota S; Wakabayashi M; Yamaguchi Y; Kiyonaga D; Mori N; Minamitani E; Masuzaki H; Kobayashi Y
J Endocrinol; 2009 Jul; 202(1):131-9. PubMed ID: 19380458
[TBL] [Abstract][Full Text] [Related]
25. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
26. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
27. Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Scott JS; Goldberg FW; Turnbull AV
J Med Chem; 2014 Jun; 57(11):4466-86. PubMed ID: 24294985
[TBL] [Abstract][Full Text] [Related]
28. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
29. In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
Mai K; Kullmann V; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
Clin Endocrinol (Oxf); 2005 Oct; 63(4):442-9. PubMed ID: 16181237
[TBL] [Abstract][Full Text] [Related]
30. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
31. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Draper N; Stewart PM
J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
[TBL] [Abstract][Full Text] [Related]
32. Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1.
Balázs Z; Nashev LG; Chandsawangbhuwana C; Baker ME; Odermatt A
Mol Cell Endocrinol; 2009 Mar; 301(1-2):117-22. PubMed ID: 19010388
[TBL] [Abstract][Full Text] [Related]
33. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
Hollis G; Huber R
Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST
Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866
[TBL] [Abstract][Full Text] [Related]
35. INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Tiwari A
IDrugs; 2010 Apr; 13(4):266-75. PubMed ID: 20373256
[TBL] [Abstract][Full Text] [Related]
36. Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Su X; Pradaux-Caggiano F; Thomas MP; Szeto MW; Halem HA; Culler MD; Vicker N; Potter BV
ChemMedChem; 2010 Jul; 5(7):1026-44. PubMed ID: 20486152
[TBL] [Abstract][Full Text] [Related]
37. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
38. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
40. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.
Shah U; Boyle CD; Chackalamannil S; Baker H; Kowalski T; Lee J; Terracina G; Zhang L
Bioorg Med Chem Lett; 2010 Mar; 20(5):1551-4. PubMed ID: 20149650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
